Cellebrite DI Ltd. $CLBT Stake Decreased by Axon Enterprise Inc.

Axon Enterprise Inc. lowered its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 59.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,509,341 shares of the company’s stock after selling 2,170,034 shares during the quarter. Cellebrite DI accounts for 100.0% of Axon Enterprise Inc.’s investment portfolio, making the stock its biggest position. Axon Enterprise Inc.’s holdings in Cellebrite DI were worth $27,213,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Voss Capital LP grew its holdings in shares of Cellebrite DI by 18.9% during the 4th quarter. Voss Capital LP now owns 8,050,000 shares of the company’s stock valued at $145,142,000 after purchasing an additional 1,277,300 shares during the last quarter. Pertento Partners LLP grew its holdings in shares of Cellebrite DI by 28.2% during the 4th quarter. Pertento Partners LLP now owns 5,959,324 shares of the company’s stock valued at $107,447,000 after purchasing an additional 1,311,109 shares during the last quarter. Invesco Ltd. grew its holdings in shares of Cellebrite DI by 58.6% during the 3rd quarter. Invesco Ltd. now owns 5,560,196 shares of the company’s stock valued at $103,030,000 after purchasing an additional 2,054,644 shares during the last quarter. Granahan Investment Management LLC grew its holdings in shares of Cellebrite DI by 16.3% during the 4th quarter. Granahan Investment Management LLC now owns 3,057,018 shares of the company’s stock valued at $55,118,000 after purchasing an additional 427,719 shares during the last quarter. Finally, Cooper Creek Partners Management LLC bought a new position in shares of Cellebrite DI during the 3rd quarter valued at $55,999,000. Institutional investors own 45.88% of the company’s stock.

Analyst Upgrades and Downgrades

CLBT has been the topic of several recent research reports. Needham & Company LLC reduced their target price on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Weiss Ratings raised shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 18th. Wall Street Zen raised shares of Cellebrite DI from a “sell” rating to a “hold” rating in a report on Sunday, March 15th. Finally, DA Davidson initiated coverage on shares of Cellebrite DI in a report on Wednesday, May 27th. They set a “buy” rating and a $20.00 target price on the stock. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $21.40.

Insider Transactions at Cellebrite DI

In other Cellebrite DI news, CRO Marcus Jewell sold 12,658 shares of the firm’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $12.77, for a total value of $161,642.66. Following the sale, the executive owned 440,101 shares of the company’s stock, valued at $5,620,089.77. This trade represents a 2.80% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders have sold 13,269 shares of company stock valued at $169,592. 5.70% of the stock is owned by company insiders.

Cellebrite DI Stock Down 2.7%

Shares of Cellebrite DI stock opened at $12.47 on Thursday. The firm has a market cap of $3.11 billion, a PE ratio of 44.54, a price-to-earnings-growth ratio of 1.59 and a beta of 1.17. Cellebrite DI Ltd. has a 12-month low of $11.02 and a 12-month high of $19.98. The company’s fifty day simple moving average is $13.15 and its two-hundred day simple moving average is $14.95.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.